Miriam Galbusera

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8346649/publications.pdf

Version: 2024-02-01

59 papers	5,927 citations	159585 30 h-index	161849 54 g-index
60 all docs	60 docs citations	60 times ranked	4289 citing authors

#	Article	IF	Citations
1	C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Advances, 2022, 6, 866-881.	5.2	31
2	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation. Frontiers in Immunology, 2022, 13, 827146.	4.8	45
3	Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis. Frontiers in Immunology, 2021, 12, 711915.	4.8	2
4	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS ONE, 2021, 16, e0261113.	2.5	25
5	Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. Frontiers in Medicine, 2020, 7, 579418.	2.6	8
6	An ExÂVivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2019, 74, 56-72.	1.9	71
7	Bleeding and Hemostasis in Acute Renal Failure. , 2019, , 630-635.e2.		1
8	Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. Journal of Immunology, 2017, 199, 1021-1040.	0.8	56
9	Prevention and Therapeutic Management of Bleeding in Dialysis Patients. , 2017, , 334-345.e1.		0
10	Liver transplantation for aHUS: still needed in the eculizumab era?. Pediatric Nephrology, 2016, 31, 759-768.	1.7	22
11	Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease. EBioMedicine, 2015, 2, 456-466.	6.1	24
12	Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. American Journal of Kidney Diseases, 2015, 66, 1067-1070.	1.9	25
13	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2002-2012.	4.5	12
14	A Novel Antibody against Human Factor B that Blocks Formation of the C3bB Proconvertase and Inhibits Complement Activation in Disease Models. Journal of Immunology, 2014, 193, 5567-5575.	0.8	14
15	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 2014, 124, 1715-1726.	1.4	288
16	Two Patients With History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations. American Journal of Transplantation, 2013, 13, 2201-2206.	4.7	51
17	ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy. Diabetes, 2013, 62, 3599-3609.	0.6	25
18	Membranous Nephropathy Associated With IgG4-Related Disease. American Journal of Kidney Diseases, 2011, 58, 272-275.	1.9	64

#	Article	IF	Citations
19	Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis. Journal of Immunology, 2011, 187, 172-180.	0.8	220
20	Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. , 2010, , 349-364.		0
21	Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thrombosis and Haemostasis, 2009, 101, 233-238.	3.4	85
22	Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice. Gene Therapy, 2009, 16, 1373-1379.	4.5	13
23	Treatment of Bleeding in Dialysis Patients. Seminars in Dialysis, 2009, 22, 279-286.	1.3	129
24	Inherited thrombotic thrombocytopenic purpura. Haematologica, 2009, 94, 166-170.	3.5	29
25	Bleeding and Hemostasis in Acute Renal Failure. , 2009, , 385-390.		0
26	Prevention and Therapeutic Management of Bleeding in Dialysis Patients. , 2008, , 445-456.		0
27	Involvement of renal tubular tollâ€like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis and Rheumatism, 2007, 56, 1569-1578.	6.7	61
28	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2006, 96, 454-464.	3.4	72
29	Thrombotic Thrombocytopenic Purpura-Then and Now. Seminars in Thrombosis and Hemostasis, 2006, 32, 081-089.	2.7	52
30	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2006, 96, 454-64.	3.4	20
31	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 2005, 106, 1262-1267.	1.4	275
32	Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood, 2005, 106, 925-928.	1.4	57
33	Activation of porcine endothelium in response to xenogeneic serum causes thrombosis independently of platelet activation. Xenotransplantation, 2005, 12, 110-120.	2.8	14
34	Complement Factor H Mutation in Familial Thrombotic Thrombocytopenic Purpura with ADAMTS13 Deficiency and Renal Involvement. Journal of the American Society of Nephrology: JASN, 2005, 16, 1177-1183.	6.1	129
35	Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thrombosis and Haemostasis, 2005, 93, 443-452.	3.4	81
36	In Response to Protein Load Podocytes Reorganize Cytoskeleton and Modulate Endothelin-1 Gene. American Journal of Pathology, 2005, 166, 1309-1320.	3.8	151

#	Article	IF	Citations
37	Platelet Dysfunction in Renal Failure. Seminars in Thrombosis and Hemostasis, 2004, 30, 579-589.	2.7	393
38	Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. Journal of Thrombosis and Haemostasis, 2004, 2, 1601-1609.	3.8	96
39	Diverse Functional Implications of ADAMTS13 Gene Mutations in Patients with TTP and Congenital Deficiency.. Blood, 2004, 104, 513-513.	1.4	5
40	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood, 2002, 100, 778-785.	1.4	200
41	Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura. Blood, 2002, 100, 3839-3842.	1.4	24
42	Verotoxin-1â€“induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood, 2001, 98, 1828-1835.	1.4	92
43	A novel interpretation of the role of von Willebrand factor in thrombotic microangiopathies based on platelet adhesion studies at high shear rate flow. American Journal of Kidney Diseases, 2000, 36, 695-702.	1.9	14
44	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. Blood, 1999, 94, 610-620.	1.4	44
45	Unrecognized Pattern of von Willebrand Factor Abnormalities in Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. Journal of the American Society of Nephrology: JASN, 1999, 10, 1234-1241.	6.1	23
46	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. Blood, 1999, 94, 610-620.	1.4	1
47	von Willebrand Factorâ€“Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolyticâ€“Uremic Syndrome. New England Journal of Medicine, 1998, 339, 1578-1584.	27.0	1,717
48	Fluid Shear Stress Modulates von Willebrand Factor Release From Human Vascular Endothelium. Blood, 1997, 90, 1558-1564.	1.4	123
49	Fluid Shear Stress Modulates von Willebrand Factor Release From Human Vascular Endothelium. Blood, 1997, 90, 1558-1564.	1.4	8
50	Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. Kidney International, 1996, 49, 282-286.	5.2	47
51	Î±1-antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. Lancet, The, 1995, 345, 224-225.	13.7	22
52	Thrombotic Thrombocytopenic Purpura: Evidence That Infusion Rather Than Removal of Plasma Induces Remission of the Disease. American Journal of Kidney Diseases, 1993, 21, 314-318.	1.9	73
53	Reversible Activation Defect of the Platelet Glycoprotein IIb-IIIa Complex in Patients With Uremia. American Journal of Kidney Diseases, 1993, 22, 668-676.	1.9	92
54	Defective Platelet Aggregation in Response to Platelet-Activating Factor in Uremia Associated With Low Platelet Thromboxane A2 Generation. American Journal of Kidney Diseases, 1992, 19, 318-325.	1.9	21

#	Article	IF	Citations
55	Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.. Journal of Clinical Investigation, 1991, 88, 774-782.	8.2	174
56	Functional implications of decreased renal cortical atrial natriuretic peptide binding in experimental diabetes.. Circulation Research, 1990, 66, 1453-1460.	4.5	15
57	Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. Kidney International, 1989, 36, 57-64.	5.2	57
58	Catecholamine receptor binding in rat kidney: Effect of aging. Kidney International, 1988, 33, 1073-1077.	5.2	26
59	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Thrombus Formation. SSRN Electronic Journal, 0, , .	0.4	1